Alonso Torres, A. M. http://orcid.org/0000-0002-7337-8384
Arévalo Bernabé, A. G.
Becerril Ríos, N. http://orcid.org/0000-0002-9444-9508
Hellín Gil, M. F. http://orcid.org/0000-0003-0402-0888
Martínez Sesmero, J. M. http://orcid.org/0000-0003-2226-8334
Meca Lallana, V. http://orcid.org/0000-0001-9418-4127
Ramió-Torrentà, Ll. http://orcid.org/0000-0002-6999-1004
Rodríguez-Antigüedad, A. http://orcid.org/0000-0002-4566-2329
Gómez Maldonado, L. http://orcid.org/0000-0002-6317-6682
Triana Junco, I.
Gómez-Barrera, M. http://orcid.org/0000-0001-8357-1279
Espinoza Cámac, N. http://orcid.org/0000-0002-8116-6963
Oyagüez, I. http://orcid.org/0000-0002-3047-6152
Article History
Accepted: 22 January 2023
First Online: 21 February 2023
Change Date: 28 April 2023
Change Type: Update
Change Details: The ESM has been exchanged.
Declarations
:
: This analysis was supported by Biogen Spain S.L.U.
: Ana María Alonso Torres has received compensation for serving on advisory boards for Biogen Spain S.L.U., Bristol Myers Squibb (BMS), Janssen, Novartis, Roche, and Sanofi; speaker honoraria from Almirall, Biogen Spain S.L.U., BMS, Janssen, Merck, Novartis, Roche, and Sanofi. Ángel Guillermo Arévalo Bernabé has received compensation for serving on advisory boards for Biogen Spain S.L.U. and Merck. Noelia Becerril Ríos has received compensation for serving on advisory boards and speaker fees from Almirall, Bayer, Biogen Spain S.L.U., BMS, Janssen, Merck, Novartis, and Sanofi. María Fuensanta Hellín Gil has received compensation for serving on advisory boards and a speaker event for Biogen Spain S.L.U. José Manuel Martínez Sesmero has received compensation for serving on advisory boards for Biogen Spain S.L.U., Merck, Roche, and Teva Pharmaceutical. Virginia Meca Lallana has received compensation for serving on scientific advisory boards and has received speaker honoraria from Almirall, Biogen Spain S.L.U., BMS, Genzyme, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Terumo, and Teva Pharmaceutical. Lluís Ramió-Torrentá has received compensation for serving on advisory boards and speaker honoraria from Almirall, Biogen Spain S.L.U., BMS, Merck, Novartis, Roche, Sanofi, and Teva Pharmaceutical. Alfredo Rodriguez-Antigüedad Zarranz has received compensation for serving on advisory boards or speaker honoraria from Biogen, BMS, Janssen, Merck‐Serono, Novartis, Roche, and Sanofi. Laura Gómez Maldonado and Inés Triana Junco are employees of Biogen Spain S.L.U. and hold shares or stocks as part of their remuneration. Manuel Gómez-Barrera, Nataly Espinoza Cámac, and Itziar Oyagüez work for Pharmacoeconomics & Outcomes Research Iberia (PORIB), an independent research organisation, which received funding pursuant to a contract with Biogen Spain S.L.U.
: Not applicable. No patient data were used.
: Not applicable.
: Not applicable.
: The questionnaire used for collection and validation of data used in the present analysis, and the model that support the findings of this study are available on reasonable request from the corresponding author.
: Not applicable.
: All authors contributed to the parameters included in the study. AMAT, AGAB, NBR, MFHG, JMMS, VML, LlRT, and ARA conceived, MGB and IO designed, and MGB conducted (collected/analysed data) the study. The first draft of the manuscript was written by MGB, NEC, and IO and all authors commented on later versions of the manuscript. All authors read and approved the final manuscript.